Analyst Price Target is $12.20
▲ +56.61% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Beyond Air in the last 3 months. The average price target is $12.20, with a high forecast of $17.00 and a low forecast of $9.00. The average price target represents a 56.61% upside from the last price of $7.79.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Beyond Air.
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) generator and delivery systems. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of persistent pulmonary hypertension of the newborn; acute viral pneumonia, including COVID-19; bronchiolitis and nontuberculous mycobacteria lung infections; and solid tumors. It operates in Israel, Ireland, Australia, and the European Union. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.